Roche (RHHBY) unveiled its proprietary, breakthrough sequencing by expansion technology, establishing a new category of next-generation ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, ...

European stock pickers are exploring established sectors such as ... and interpretable models. In the realm of diagnostics, Roche has expanded its digital pathology capabilities by integrating over 20 ...

Diagnostics may not be as profitable as Pharmaceuticals ... Concluding Thoughts: Is Roche Stock A “Best Buy” Within Big Pharma In 2025? As a Roche shareholder myself, am I looking forward ...

The Diagnostics division’s sales rose 4% year ... However, pipeline setbacks weigh on the stock. Roche also expects loss of exclusivity for key drugs to impact adversely sales to the tune ...

Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...

If you ever had cancer or were tested for it, there’s a good chance Roche Tissue Diagnostics played a role behind the scenes. The Tucson-area company has emerged as a global leader in ...

Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price of $9 per ...